Advertisement

Research Article Free access | 10.1172/JCI118370

Targeted tumor killing via an intracellular antibody against erbB-2.

J Deshane, G P Siegal, R D Alvarez, M H Wang, M Feng, G Cabrera, T Liu, M Kay, and D T Curiel

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Deshane, J. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Siegal, G. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Alvarez, R. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Wang, M. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Feng, M. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Cabrera, G. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Liu, T. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Kay, M. in: JCI | PubMed | Google Scholar

Gene Therapy Program, University of Alabama at Birmingham, 35294, USA.

Find articles by Curiel, D. in: JCI | PubMed | Google Scholar

Published December 1, 1995 - More info

Published in Volume 96, Issue 6 on December 1, 1995
J Clin Invest. 1995;96(6):2980–2989. https://doi.org/10.1172/JCI118370.
© 1995 The American Society for Clinical Investigation
Published December 1, 1995 - Version history
View PDF
Abstract

Specific killing of erbB-2-overexpressing tumor cells can be achieved using expression of an intracellular antibody directed against the erbB-2 oncoprotein. We have developed a strategy using a recombinant adenovirus encoding an anti-erbB-2 single chain antibody to achieve targeted tumor cell killing in vivo and can show significantly prolonged survival of animals carrying a human ovarian carcinoma tumor burden within their peritoneal cavities. This strategy of gene therapy for ovarian carcinoma offers the potential to achieve highly specific, targeted killing of human tumor cells and thus establishes the rationale to undertake human clinical trials on this basis.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (December 1, 1995): No description
Advertisement
Advertisement